Monday, October 17, 2022
Biogen Inc. and Eisai Co. have partnered together on experimental drug, lecanemab, which they say significantly slowed symptoms of Alzheimer’s. This makes it the first medicine to blunt progression of dementia in a largely definitive study.
These findings mark a major milestone who have been attempting for decades to stop the disease. The medicine does not restore mental capacity or totally stop memory loss, but Biogen and Eisai were able to show the reduction of cognitive decline with people showing early signs of the disease by 27% over a year and a half. The trial was able to meet every goal it set, including measures of mental function and ability to perform daily activities, however, side effects include brain swelling and bleeding, although this was rare.
For more information see Michelle Fay Cortez and Robert Langreth “Alzheimer’s Progression Slowed by Drug in Major Trial”, Bloomberg Technology, September 28, 2022.
Special thanks to Lewis Saret (Attorney, Washington, D.C.) for bringing this article to my attention.
Post a comment